Associations between sarcopenia and gut microbiota in patients (pts) with metastatic renal cell carcinoma (mRCC) and breast cancer (BC)
Z.B. Zengin, et al.
These are the first data to associate sarcopenia with composition of the gut microbiome in pts with cancer. Mechanistic studies are needed to determine if there is a causal interplay.
Gut microbiota and efficacy of immune-checkpoint inhibitors (ICIs) in patients (pts) with advanced solid tumor: SCRUM-Japan MONSTAR-SCREEN
Sawada, et al.
Diversity of gut microbiota by the OTU was significantly associated with higher ORR and longer PFS on ICIs in pts with advanced solid tumor. These results indicated the potential of the OTU as a putative tumor-agnostic biomarker for the efficacy of ICIs beyond MSI, bTMB and tTMB status. Further study with shotgun and single cell metagenome analyses are ongoing.
Clinical value of pre-treatment T-Cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy.
Abe, et al.
Increased pre-treatment TCR clonality and reduced diversity are associated with improved RR and PFS, but not OS in NSCLC patients with high PD-L1 treated with pembrolizumab monotherapy. Reduced eveness and increased clonality was correlated with increased risk of immune related adverse events. Further maturation of this cohort will demonstrate whether the circulating pre-treatment TCR repertoire is a prognostic factor for immune checkpoint inhibition.
Impact of immune checkpoint blockade therapy according to CD274 copy number alterations: a retrospective study in the ProfiLER cohort
Hodroj, et al.
In this retrospective study, CD274 CNA gain/amplification is associated with OS improvement when patients are treated with ICBD. Further prospective studies are needed to confirm CD274 gain/amplification as a predictive biomarker for ICBDs response.
Defining subset-wise myeloid responses to immune checkpoint blockade in melanoma
Cooper, et al.
This work confirms ICB-dependent modulation of circulating monocytes, with novel observations regarding subset-wise myeloid responses. This demonstrates the potential clinical utility of circulating immune populations as diagnostic, predictive and prognostic markers in patients with MM.
Biomarker Analysis of Men With Enzalutamide (Enza)-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Pembrolizumab (Pembro) + Enza in KEYNOTE-199
J.N. Graff, et al.
In this biomarker analysis of KEYNOTE-199 C4-C5, PD-L1 CPS and TcellinfGEP were not significantly associated with clinical outcome. Despite the low prevalence of TMB ≥175 mut/exome, TMB was positively associated with outcomes of pembro +
enza in pts with mCRPC. The sample sizes for the exploratory analyses were small, and results should be interpreted with caution.